Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome

a non-insulin-dependent, metabolic syndrome technology, applied in the direction of biocide, plant ingredients, sugar derivatives, etc., can solve the problems of increasing the risk of cardiac arrhythmias, many unwanted adverse effects, and patients' hypertension and dyslipidemia, so as to suppress the total cholesterol level, suppress appetite, and suppress fasting plasma triglycerides
US20080051341A1Inactive Publication Date: 2008-02-28STEVIA LTD
5 Cites 14 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
STEVIA LTD
Publication Date
2008-02-28
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and / or the metabolic syndrome. The unique chemical structures of bicyclo[3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and / or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and / or hypertension. In a combination drug which also comprise a soy protein, and / or soy fiber and / or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a continuation of U.S. application Ser. No. 10 / 933,297 filed Sep. 3, 2004, which is a division of 10 / 210,787 filed Jul. 31, 2002, which is a continuation of PCT / DK01 / 00075 filed Feb. 1, 2001. The prior applications set forth above are hereby incorporated by reference in their entirety.TECHNICAL FIELD

[0002] The present invention relates to a new medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension, metabolic syndromes and other conditions in mammals. BACKGROUND ART

[0003] Diabetes is a common disease that has a prevalence of 2-4% in the population. Non-insulin dependent diabetes mellitus comprises about 85% of diabetes most commonly occurring at the age above 40 years. The incidence of non-insulin dependent diabetes mellitus is increasing and is at a global level expected to surpass 200 million subjects at year 2010.

[0004] Diabetes is associated with increased morbidity and a 2-4-fold increase in mortality primarily due to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More